Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Oncaspar Generic Name & Formulations
Legal Class
Rx
General Description
Pegaspargase 750 IU/mL; soln for IV or IM inj; preservative-free.
Pharmacological Class
Asparagine-specific enzyme.
How Supplied
Single-dose vial (5mL)—1
Manufacturer
Generic Availability
NO
Oncaspar Indications
Indications
First-line acute lymphoblastic leukemia (including patients with asparaginase hypersensitivity), as part of a multi-agent chemotherapy regimen.
Oncaspar Dosage and Administration
Adults and Children
Premedicate with APAP, diphenhydramine, and famotidine 30–60mins prior to initiation. Give by IV inj over 1–2hrs or by IM inj (max 2mL/inj site). Treat every 14 days. ≤21yrs: 2500 IU/m2. >21yrs: 2000 IU/m2. Dose modifications: see full labeling.
Oncaspar Contraindications
Contraindications
History of pancreatitis, serious hemorrhage, or thrombosis with prior L-asparaginase therapy. Severe hepatic impairment.
Oncaspar Boxed Warnings
Not Applicable
Oncaspar Warnings/Precautions
Warnings/Precautions
Observe patients for 1hr post-dose. Have medical treatment for anaphylaxis readily available. Permanently discontinue for Grade 3/4 infusion/hypersensitivity reactions, confirmed pancreatitis, or severe thrombosis. Monitor bilirubin and transaminases at least weekly during treatment cycles through at least 6wks after last dose. Monitor serum glucose, coagulation parameters. Discontinue if severe hemorrhage or liver toxicity occurs. Advise females of reproductive potential to use effective non-hormonal contraception during and for 3months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1month after last dose).
Oncaspar Pharmacokinetics
See Literature
Oncaspar Interactions
Interactions
May increase the risk of glucocorticoid-induced toxicities.
Oncaspar Adverse Reactions
Adverse Reactions
Hypoalbuminemia, elevated transaminases/bilirubin, febrile neutropenia, hypertriglyceridemia, hyperglycemia, pancreatitis, coagulopathy, embolic/thrombotic events, hypersensitivity.
Oncaspar Clinical Trials
See Literature
Oncaspar Note
Not Applicable
Oncaspar Patient Counseling
See Literature
